Clinical Trial

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-21.
Status change: Not Yet Recruiting → Recruiting 2025-06-26
Trial Details
NCT Number NCT06946927
Lead Sponsor Jemincare
Conditions NSCLC (Advanced Non-small Cell Lung Cancer)
Enrollment 72 participants
Start Date 2025-06-06
Primary Completion 2026-02 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-01